F
Fabio A.B. Schutz
Researcher at Harvard University
Publications - 86
Citations - 9410
Fabio A.B. Schutz is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 29, co-authored 81 publications receiving 7604 citations. Previous affiliations of Fabio A.B. Schutz include Niigata University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma
Markus Riester,Lillian Werner,Joaquim Bellmunt,Shamini Selvarajah,Elizabeth A. Guancial,Barbara A. Weir,Edward C. Stack,Rachel S. Park,Robert O'Brien,Fabio A.B. Schutz,Toni K. Choueiri,Sabina Signoretti,Josep Lloreta,Luigi Marchionni,Enrique Gallardo,Federico Rojo,Denise Garcia,Yvonne Chekaluk,David J. Kwiatkowski,Bernard H. Bochner,William C. Hahn,William C. Hahn,Azra H. Ligon,Justine A. Barletta,Massimo Loda,David M. Berman,Philip W. Kantoff,Franziska Michor,Jonathan E. Rosenberg +28 more
TL;DR: The F11R, PFDN2, PPOX, USP21, and DEDD genes, all located on 1q23.3, were closely associated with poor outcome and exploration of this finding in other disease states may be useful for the early identification of patients with poor-risk urothelial carcinoma.
Journal ArticleDOI
IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Enrique Grande,Matthew D. Galsky,J.A. Arranz Arija,M. De Santis,Ian D. Davis,U. De Giorgi,Marina Mencinger,Eiji Kikuchi,X. Garcia del Muro,Mahmut Gumus,Mustafa Ozguroglu,A. Rezazadeh Kalebasty,Sung-Ji Park,Boris Alekseev,Fabio A.B. Schutz,J-R. Li,Almut Mecke,Sanjeev Mariathasan,A. Thåström,Aristotle Bamias +19 more
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer
Paul L. Nguyen,Fabio A.B. Schutz,Karen E. Hoffman,Jim C. Hu,Joshua A. Beckman,Toni K. Choueiri +5 more
TL;DR: In a pooled analysis of randomized trials in unfavorable-risk prostate cancer, ADT use was not associated with an increased risk of cardiovascular death but was associated with a lower risk of PCSM and all-cause mortality.
Journal ArticleDOI
Haematologic toxicities associated with the addition of bevacizumab in cancer patients
TL;DR: Bvacizumab is associated with a lower risk of anaemia and increased risks of neutropenia, thrombocytopenia and febrile neutropania, a meta-analysis performed to determine the incidence and risk of haematologic toxicities associated with bevacIZumab.
Journal ArticleDOI
Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid
TL;DR: Vinflunine is currently approved in Europe for the treatment of second-line TCCU and is currently being developed in other malignancies, where it has been shown to have predictable and manageable adverse effects, such as neutropenia, anemia, constipation and fatigue.